State Street Corp Has $39.34 Million Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

State Street Corp lessened its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 0.1% in the third quarter, HoldingsChannel.com reports. The fund owned 2,823,817 shares of the company’s stock after selling 3,003 shares during the period. State Street Corp’s holdings in Day One Biopharmaceuticals were worth $39,336,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. First Turn Management LLC acquired a new position in Day One Biopharmaceuticals during the third quarter worth about $13,204,000. GSA Capital Partners LLP bought a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter valued at approximately $825,000. Algert Global LLC increased its position in Day One Biopharmaceuticals by 248.8% during the 3rd quarter. Algert Global LLC now owns 71,487 shares of the company’s stock worth $996,000 after purchasing an additional 50,990 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Day One Biopharmaceuticals by 14.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company’s stock worth $7,069,000 after purchasing an additional 64,700 shares in the last quarter. Finally, Vestal Point Capital LP lifted its stake in Day One Biopharmaceuticals by 100.0% in the 3rd quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock valued at $34,825,000 after purchasing an additional 1,250,000 shares during the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Trading Up 2.6 %

NASDAQ DAWN opened at $12.79 on Friday. The firm has a market capitalization of $1.29 billion, a PE ratio of -12.42 and a beta of -1.51. The business’s 50-day moving average price is $14.07 and its two-hundred day moving average price is $14.01. Day One Biopharmaceuticals, Inc. has a 12 month low of $11.94 and a 12 month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.58. The company had revenue of $93.76 million for the quarter, compared to the consensus estimate of $15.05 million. During the same period in the prior year, the firm posted ($0.54) earnings per share. As a group, analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.88 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Day One Biopharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $35.71.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $16.10, for a total value of $161,000.00. Following the sale, the insider now owns 1,057,535 shares of the company’s stock, valued at $17,026,313.50. This trade represents a 0.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last quarter, insiders have sold 51,745 shares of company stock valued at $748,567. 8.40% of the stock is owned by company insiders.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.